578 related articles for article (PubMed ID: 18172553)
21. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling.
Martin A; Liu S; David V; Li H; Karydis A; Feng JQ; Quarles LD
FASEB J; 2011 Aug; 25(8):2551-62. PubMed ID: 21507898
[TBL] [Abstract][Full Text] [Related]
22. Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia.
Barros NM; Hoac B; Neves RL; Addison WN; Assis DM; Murshed M; Carmona AK; McKee MD
J Bone Miner Res; 2013 Mar; 28(3):688-99. PubMed ID: 22991293
[TBL] [Abstract][Full Text] [Related]
23. Excessive Osteocytic Fgf23 Secretion Contributes to Pyrophosphate Accumulation and Mineralization Defect in Hyp Mice.
Murali SK; Andrukhova O; Clinkenbeard EL; White KE; Erben RG
PLoS Biol; 2016 Apr; 14(4):e1002427. PubMed ID: 27035636
[TBL] [Abstract][Full Text] [Related]
24. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.
Sitara D; Razzaque MS; Hesse M; Yoganathan S; Taguchi T; Erben RG; Jüppner H; Lanske B
Matrix Biol; 2004 Nov; 23(7):421-32. PubMed ID: 15579309
[TBL] [Abstract][Full Text] [Related]
25. A mosaic mutation of phosphate-regulating gene with homologies to endopeptidases on the X chromosome (PHEX) in X-linked hypophosphatemic rickets with mild bone phenotypes.
Asano S; Sako S; Funasaki Y; Takeshita Y; Niida Y; Takamura T
Endocr J; 2021 Sep; 68(9):1135-1141. PubMed ID: 33907069
[TBL] [Abstract][Full Text] [Related]
26. Eldecalcitol Causes FGF23 Resistance for Pi Reabsorption and Improves Rachitic Bone Phenotypes in the Male Hyp Mouse.
Kaneko I; Segawa H; Ikuta K; Hanazaki A; Fujii T; Tatsumi S; Kido S; Hasegawa T; Amizuka N; Saito H; Miyamoto KI
Endocrinology; 2018 Jul; 159(7):2741-2758. PubMed ID: 29878089
[TBL] [Abstract][Full Text] [Related]
27. Dentoalveolar Defects in the
Zhang H; Chavez MB; Kolli TN; Tan MH; Fong H; Chu EY; Li Y; Ren X; Watanabe K; Kim DG; Foster BL
J Dent Res; 2020 Apr; 99(4):419-428. PubMed ID: 31977267
[TBL] [Abstract][Full Text] [Related]
28. Dysregulated gene expression in the primary osteoblasts and osteocytes isolated from hypophosphatemic Hyp mice.
Miyagawa K; Yamazaki M; Kawai M; Nishino J; Koshimizu T; Ohata Y; Tachikawa K; Mikuni-Takagaki Y; Kogo M; Ozono K; Michigami T
PLoS One; 2014; 9(4):e93840. PubMed ID: 24710520
[TBL] [Abstract][Full Text] [Related]
29. ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate.
David V; Martin A; Hedge AM; Drezner MK; Rowe PS
Am J Physiol Renal Physiol; 2011 Mar; 300(3):F783-91. PubMed ID: 21177780
[TBL] [Abstract][Full Text] [Related]
30. Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model.
Nakatani T; Ohnishi M; Razzaque MS
FASEB J; 2009 Nov; 23(11):3702-11. PubMed ID: 19584304
[TBL] [Abstract][Full Text] [Related]
31. Mineralized tissues in hypophosphatemic rickets.
Robinson ME; AlQuorain H; Murshed M; Rauch F
Pediatr Nephrol; 2020 Oct; 35(10):1843-1854. PubMed ID: 31392510
[TBL] [Abstract][Full Text] [Related]
32. Sclerostin Antibody Treatment Increases Bone Mass and Normalizes Circulating Phosphate Levels in Growing Hyp Mice.
Carpenter KA; Ross RD
J Bone Miner Res; 2020 Mar; 35(3):596-607. PubMed ID: 31743490
[TBL] [Abstract][Full Text] [Related]
33. Tissue-specific mineralization defects in the periodontium of the Hyp mouse model of X-linked hypophosphatemia.
Coyac BR; Falgayrac G; Baroukh B; Slimani L; Sadoine J; Penel G; Biosse-Duplan M; Schinke T; Linglart A; McKee MD; Chaussain C; Bardet C
Bone; 2017 Oct; 103():334-346. PubMed ID: 28764922
[TBL] [Abstract][Full Text] [Related]
34. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice.
Aono Y; Hasegawa H; Yamazaki Y; Shimada T; Fujita T; Yamashita T; Fukumoto S
J Bone Miner Res; 2011 Apr; 26(4):803-10. PubMed ID: 20939065
[TBL] [Abstract][Full Text] [Related]
35. Ontogeny of Phex/PHEX protein expression in mouse embryo and subcellular localization in osteoblasts.
Thompson DL; Sabbagh Y; Tenenhouse HS; Roche PC; Drezner MK; Salisbury JL; Grande JP; Poeschla EM; Kumar R
J Bone Miner Res; 2002 Feb; 17(2):311-20. PubMed ID: 11811562
[TBL] [Abstract][Full Text] [Related]
36. Expression and distribution of SIBLING proteins in the predentin/dentin and mandible of hyp mice.
Zhang B; Sun Y; Chen L; Guan C; Guo L; Qin C
Oral Dis; 2010 Jul; 16(5):453-64. PubMed ID: 20233318
[TBL] [Abstract][Full Text] [Related]
37. Retinol deprivation partially rescues the skeletal mineralization defects of Phex-deficient Hyp mice.
Seitz S; Rendenbach C; Barvencik F; Streichert T; Jeschke A; Schulze J; Amling M; Schinke T
Bone; 2013 Mar; 53(1):231-8. PubMed ID: 23266491
[TBL] [Abstract][Full Text] [Related]
38. Survey of the enthesopathy of X-linked hypophosphatemia and its characterization in Hyp mice.
Liang G; Katz LD; Insogna KL; Carpenter TO; Macica CM
Calcif Tissue Int; 2009 Sep; 85(3):235-46. PubMed ID: 19609735
[TBL] [Abstract][Full Text] [Related]
39. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity.
Liu S; Rowe PS; Vierthaler L; Zhou J; Quarles LD
J Endocrinol; 2007 Jan; 192(1):261-7. PubMed ID: 17210763
[TBL] [Abstract][Full Text] [Related]
40. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.
Rowe PS
Crit Rev Eukaryot Gene Expr; 2012; 22(1):61-86. PubMed ID: 22339660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
